Logo Prima Biomed

Welcome to the Newsroom

24 July 2015

Prima BioMed raises A$10M through Share Purchase Plan


SYDNEY, AUSTRALIA - Prima BioMed Ltd (ASX: PRR; NASDAQ: PBMD) (“Prima” or the “Company”), announces that it has successfully raised A$10M via a Share Purchase Plan (SPP). The proceeds from the SPP will be used to fund the Company’s IMP321 clinical trial program.

As announced on Tuesday 7 July 2015, the SPP allowed eligible shareholders to subscribe for up to A$15,000 worth of new shares at 5.0 cents per share. Due to overwhelming shareholder demand, the Board exercised its right to increase the amount raised under the SPP from A$5M to A$10M.